Journal of the American College of Cardiology · 2007
The truth and consequences of the COURAGE trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kereiakes Dean J, Teirstein Paul S, Sarembock Ian J, Holmes David R, Krucoff Mitchell W, O'Neill William W, Waksman Ron, Williams David O, Popma Jeffrey J, Buchbinder Maurice, Mehran Roxana, Meredith Ian T, Moses Jeffrey W, Stone Gregg W
Аннотация
Percutaneous coronary intervention (PCI) has played an integral role in the therapeutic management strategies for patients who present with either acute coronary syndromes or stable angina pectoris. The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial enrolled patients with chronic stable angina and at least 1 significant (> or =70%) angiographic coronary stenosis who were randomly assigned to an initial treatment of either PCI in conjunction with optimal medical therapy or optimal medical therapy alone. Although the initial management strategy of PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events, improvement in angina-free status and a reduction in the requirement for subsequent revascularization was observed. An in-depth analysis of the COURAGE trial design and execution is provided.
Предметные рубрики MeSH
Adrenergic beta-AntagonistsAngina, UnstableAngioplasty, Balloon, CoronaryAspirinCoronary AngiographyCoronary StenosisHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMyocardial IschemiaPatient CompliancePlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicRetreatmentTreatment Outcome